Dolutegravir Overview Categories 6 Anti-infective drugs6.5 Antivirals, systemic6.5.2 Antiretroviral drugs Page headings Overview Primary Characterstics Indications Pharmacokinetics Contraindications Drug Interactions Side Effects Dosage High Risk Groups Warning / Precautions Storage Conditions Interference in Pathology Brands of Dolutegravir Manufacturers of Dolutegravir Primary Characterstics Indications Back to top Pharmacokinetics Back to top Contraindications Back to top Drug Interactions Back to top Side Effects Back to top Dosage Dolutegravir's dosage details are as follows: Dose Single Dose Frequency Route Instructions Adult Dosage 0 to 50 mg25 (25)As recommended.POPatients infected with HIV-1 without suspected resistance to the integrase class50 mg50 (50)As recommended.POpatient infected with HIV-1 without suspected resistance to the integrase classwhen co-administered with some medicines (e.g. efavirenz, nevirapine, tipranavir/ritonavir, or rifampicin) i50 mg50 (50)As recommended.POPatients infected with HIV-1 with resistance to the integrase class Paedriatic Dosage (20kg) 0 to 50 mg25 (25)As recommended.POpediatric patients aged 12 years and older and weighing at least 40 kg Neonatal Dosage (3kg) No data regarding the neonatal dosage details of Dolutegravir is available. High Risk Groups Back to top Warning / Precautions Back to top Storage Conditions Back to top Interference in Pathology Back to top Brands / Trade Names of Dolutegravir Back to top Manufacturers of Dolutegravir in Pakistan Back to top Previous Drug Generic - Next Drug Generic